A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer

Robinson, William R.; Luck, Mindy; Omar, Holly; Blades, Nancy; Morris, Kathy; Coscia, John

doi:10.1007/s00520-005-0798-3

Cited by 7 publications

(3 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies concluded that tamoxifen reduces bone resorption, turnover, and stimulates bone formation by mimicking the effects of estrogen and inhibiting osteoclasts 19,20 . Changes in BMD depend on menopausal status as well as on the class of drug used 21,22 . Long‐term use of tamoxifen in women with breast cancer has been shown to have negative effects on bone metabolism in premenopausal women and a beneficial effect in postmenopausal women 23 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

Ustaoğlu

Bulut

Üyetürk

et al. 2020

Special Care in Dentistry

View full text Add to dashboard Cite

AimTo study the dental and periodontal status of women with breast cancer (BCa) having tamoxifen or aromatase inhibitors (AIs) treatment in comparison with control healthy women.MethodsFifty‐one women on tamoxifen therapy, 52 women on AIs therapy and 52 systemically healthy controls were included in the study. The total number of teeth, the number of teeth indicated for extraction, the number of decayed teeth, and the duration of medication were recorded. Periodontal status was evaluated with gingival index (GI); plaque index (PI); bleeding on probing (BOP); probing depth (PD) and clinical attachment loss (CAL).ResultsThe lowest number of teeth and decayed teeth was found in AIs users (P < .001 and P = .003 respectively). The highest CAL value was seen in AIs users (P = .042) whereas no significant difference was found between the groups in terms of PI, GI, and PD (P = .102, P = .233, and P = .306, respectively). Lower PI was observed in patients using AIs for less than 2 years (P = .048).ConclusionsWhile tamoxifen did not affect the dental and periodontal condition, AIs medication adversely affected the dental and periodontal condition by more tooth loss and higher CAL.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

Ustaoğlu

Bulut

Üyetürk

et al. 2020

Special Care in Dentistry

View full text Add to dashboard Cite

show abstract

“…Certain breast cancer therapies may accelerate bone loss. For example, chemotherapy is associated with premature ovarian failure and subsequent loss of bone mineral density [14, 56, 57]. In addition, supportive medications used with chemotherapy often include glucocorticoids which in themselves can induce osteoporosis [58].…”

Section: Discussionmentioning

confidence: 99%

Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer

Taichman

Havens

Poznak

2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

Current adjuvant treatment modalities for breast cancer that express the estrogen receptor or progesterone receptor include adjuvant anti-estrogen therapies, and tamoxifen and aromatase inhibitors. Bone, including the jaw, is an endocrine-sensitive organ, as are other oral structures. This review examines the potential links between adjuvant anti-estrogen treatments in postmenopausal women with hormone receptor positive breast cancer and oral health. A search of PubMed, EMBASE, CENTRAL, and the Web of Knowledge was conducted using combinations of key terms “breast,” “cancer,” “neoplasm,” “Tamoxifen,” “Aromatase Inhibitor,” “chemotherapy,” “hormone therapy,” “alveolar bone loss,” “postmenopausal bone loss,” “estrogen,” “SERM,” “hormone replacement therapy,” and “quality of life.” We selected articles published in peer-reviewed journals in the English. The authors found no studies reporting on periodontal diseases, alveolar bone loss, oral health, or oral health-related quality of life in association with anti-estrogen breast cancer treatments in postmenopausal women. Periodontal diseases, alveolar bone density, tooth loss, and conditions of the soft tissues of the mouth have all been associated with menopausal status supporting the hypothesis that the soft tissues and bone of the oral cavity could be negatively affected by anti-estrogen therapy. As a conclusion, the impact of adjuvant endocrine breast cancer therapy on the oral health of postmenopausal women is undefined. The structures of the oral cavity are influenced by estrogen; therefore, anti-estrogen therapies may carry the risk of oral toxicities. Oral health care for breast cancer patients is an important but understudied aspect of cancer survivorship.

show abstract

“…Changes in body composition, especially losses in lean mass, are associated with a reduction in physical function and quality of life (Broeckel, Jacobsen, Balducci, Horton, & Lyman, 2000;Greep et al, 2003;Robinson et al, 2005;Shapiro et al, 2001;Tisdale, 2002).…”

mentioning

confidence: 99%

Body composition and bone mineral density in breast cancer survivors and non-cancer controls: A 12- to 15-month follow-up

et al. 2018

View full text Add to dashboard Cite

While prognosis for breast cancer in women has improved, adverse side effects of treatments may negatively affect body composition and bone mineral density (BMD). This study assessed body composition and BMD changes in breast cancer survivors (BCS) (n = 10, 57.9 ± 5.7 years) and age-matched women (non-cancer, n = 10, 56.5 ± 4.3 years) over a 12- to 15-month period via dual-energy X-ray absorptiometry. No differences were observed between groups at baseline except forearm BMD values were lower in BCS (BCS: 0.462 ± 0.070 g/cm ; Control: 0.539 ± 0.052 g/cm , p = .012). Body fat increased in both groups compared to baseline (BCS: 38.3-39.6 kg, p = .013; Control: 38.2-39.5 kg, p = .023) at the follow-up. Significant decreases in BMD at the lumbar spine, femoral neck, total femur and ulna were observed in both groups. Breast cancer survivors had a greater decrease in left femoral neck BMD. While BCS demonstrated lower baseline forearm BMD values and a greater decrease in left femoral neck BMD, both groups showed an increase in body fat and decrease in forearm BMD. These findings support the implementation of interventions to improve body composition and BMD in both BCS and women without cancer.

show abstract

A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer

Cited by 7 publications

References 12 publications

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross‐sectional study

Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer

Body composition and bone mineral density in breast cancer survivors and non-cancer controls: A 12- to 15-month follow-up

Contact Info

Product

Resources

About